Reuters logo
BRIEF-Eli Lilly announces phase 3 RANGE Urothelial cancer trial of CYRAMZA met primary endpoint
May 31, 2017 / 10:53 AM / in 5 months

BRIEF-Eli Lilly announces phase 3 RANGE Urothelial cancer trial of CYRAMZA met primary endpoint

May 31 (Reuters) - Eli Lilly and Co:

* Lilly announces phase 3 RANGE Urothelial cancer trial of cyramza® (ramucirumab) met primary endpoint, improving progression-free survival

* Eli Lilly and Co - ‍trial met primary endpoint​

* Says it anticipates that overall survival results are likely to be required for global regulatory submissions

* Eli Lilly and Co - although primary endpoint has been met, Lilly anticipates overall survival results are likely to be required for global regulatory submissions

* Says final OS results are currently expected in mid-2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below